Trial Information
Inclusion Criteria:
- Age > 18
- Hemodynamicaly stable
- Hemoptysis of varying etiologies
- Coumadin treatment will be switched to clexane or heparine
Exclusion Criteria:
- Age < 18
- Hemodinamicaly unstable
- Massive hemoptysis ( > 200 ml / day)
- Renal failure: creatinine > 3, renal replacement treatment
- Hepatic failure: bilirubin > 2 mg/dl, AST > 3 of upper normal limit level
- Coagulation disorders, INR> 2.
- Hypesensitivity to tranexamic acid
- Pregnant woman
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Outcome Measure:
bleeding stops
Outcome Time Frame:
1 year
Safety Issue:
No
Principal Investigator
David Shitrit, Dr.
Investigator Role:
Principal Investigator
Investigator Affiliation:
Meir Medical Center, Kfar Saba, Israel
Authority:
Israel: Ethics Commission
Study ID:
0096-11-MMC
NCT ID:
NCT01496196
Start Date:
January 2012
Completion Date:
February 2014
Related Keywords:
- Hemoptisis
- hemoptisis
- bleeding
- tranexamic acid